
Uncategorized - June 1, 2015
Symphogen Publishes 3 Papers
Symphogen, a biopharmaceutical company developing recombinant antibody mixtures, published two papers with new clinical data for its lead anti-EGFR antibody mixture, Sym004, in the journals Cancer Discovery and in Cancer Chemotherapy and Pharmacology. In addition, a paper in Clinical Cancer Research described preclinical findings relating to the company’s pan-HER product candidate, Sym013, a mixture of six antibodies targeting each of […]